As our focus was the inhibitory effect of AEE788 on HER2, we selected a panel of breast cancer cell lines with naturally varying ER and HER2 expression levels that modelled endocrine-resistant and -sensitive disease. This evidence concerns the gene ERBB2 and breast carcinoma.